Skip to main content
XNCR
NASDAQ Life Sciences

Xencor Reports Strong Q4/FY2025 Results, Extends Cash Runway Through 2028, and Secures New Royalties

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.98
Mkt Cap
$855.497M
52W Low
$6.92
52W High
$18.69
52W Position info
73% above low
Off High info
36% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

XNCR sits 73% above its 52-week low of $6.92.

Summary

Xencor announced significantly improved financial results for Q4 and full-year 2025, extended its cash runway through 2028, and secured an estimated $100M-$120M in new royalty revenue from a patent extension.


Key Events · Earnings and Guidance · XNCR

  • Strong Financial Performance

    Reported a significant reduction in net loss for FY2025 to $(91.9) million from $(232.6) million in 2024, alongside increased total revenue to $125.6 million.

  • Extended Cash Runway

    Projected cash, cash equivalents, and marketable debt securities of $400M-$430M by end of 2026, providing sufficient funding through 2028.

  • New Royalty Revenue Stream

    Secured a U.S. patent extension for its Xtend Fc domain, estimated to generate $100M-$120M in additional royalty revenue from Ultomiris through 2028.

  • Pipeline Advancement

    Multiple clinical programs progressing, including XmAb819 with dose expansion cohorts open and plans for a pivotal study in 2027, and XmAb412 initiating a first-in-human study in 2H26.


Analysis · XNCR · Life Sciences

This 8-K details Xencor's strong financial performance for 2025, marked by a substantial reduction in net loss and an increase in total revenue. Critically for a biotech, the company has extended its cash runway through 2028, significantly de-risking its operations. Furthermore, the issuance of a U.S. patent extension for its Xtend Fc domain is expected to generate $100 million to $120 million in additional royalty revenue from Ultomiris through 2028. These financial strengths, combined with continued progress across its clinical pipeline, including advancing XmAb819 towards a pivotal study and initiating a first-in-human study for XmAb412, provide a robust outlook for the company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XNCR was trading at $11.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $855.5M. The 52-week trading range was $6.92 to $18.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XNCR - Latest Insights

XNCR
Nov 04, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $34.36 info
Change: -$1.64 (-5%) info
Market Cap: $2.578B info
XNCR
Nov 04, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $34.98
Real-time Price: $34.36 info
Change: -$0.615 (-2%) info
Market Cap: $2.578B info
XNCR
Oct 26, 2026, 1:00 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $30.18
Real-time Price: $34.36 info
Change: +$4.18 (+14%) info
Market Cap: $2.578B info
XNCR
Oct 26, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.02
Real-time Price: $34.36 info
Change: +$0.3365 (+0.99%) info
Market Cap: $2.578B info
XNCR
Oct 25, 2026, 4:35 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.55
Real-time Price: $34.36 info
Change: +$8.81 (+34%) info
Market Cap: $2.578B info